Mounjaro® (tirzepatide) is a once-weekly injectable treatment for weight management. It works by activating two key hormone pathways—GLP-1 and GIP—helping reduce appetite, control cravings, and support substantial weight loss when combined with healthy lifestyle changes. Its dual action makes it one of the most effective medical treatments for obesity available today.
Mounjaro must be increased gradually to reduce side effects:
Weeks 1–4: 2.5 mg once weekly
Weeks 5–8: 5 mg once weekly
Weeks 9–12: 7.5 mg once weekly
Weeks 13–16: 10 mg once weekly
Weeks 17–20: 12.5 mg once weekly
Week 21 onwards (maintenance): 15 mg once weekly
Your clinician will guide you to the dose that suits your goals and tolerability.
Clinical studies show exceptional results with tirzepatide:
Up to 21% average body-weight reduction at higher doses over ~72 weeks
Many patients experience significant appetite reduction and improved eating control within the first few weeks
These results make Mounjaro one of the leading medical options for weight loss worldwide.
Mounjaro may be suitable for adults who:
Have a BMI ≥30, or
Have a BMI ≥27 with a weight-related condition (e.g., high blood pressure, prediabetes, high cholesterol).
Reduces hunger and “food noise”
Helps regulate portion sizes
Supports long-term behavioural changes
Enhances satiety between meals
Works best alongside diet and lifestyle adjustments
